Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells

Leukemia

Volumn 27, Issue 5, 2013, Pages 1127-1138

  Kustikova, O S ^a   Schwarzer, A ^a   Stahlhut, M ^a   Brugman, M H ^a,b   Neumann, T ^a   Yang, M ^a   Li, Z ^a   Schambach, A ^a   Heinz, N ^a   Gerdes, S ^c   Roeder, I ^c   Ha, T C ^a   Steinemann, D ^a   Schlegelberger, B ^a   Baum, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

gene therapy; MDS; Mecom; quiescence; transcription factor; transformation

Indexed keywords

CYCLINE; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EVI1; UNCLASSIFIED DRUG;

ABCA1 GENE; ALDH1A1 GENE; ANIMAL CELL; ARTICLE; BRCA2 GENE; CANCER CELL CULTURE; CDKN1B GENE; CDKN1C GENE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; EPCAM GENE; EVI1 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GROWTH INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; MYELOBLAST; MYELOID PROGENITOR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRECANCER; PRIORITY JOURNAL; RAD51 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DNA-BINDING PROTEINS; GRANULOCYTE PRECURSOR CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENES; TRANSCRIPTION FACTORS;

EID: 84877622988     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.355     Document Type: Article

References (56)

1. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54: 831-840.
2. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
3. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
4. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, Kim HJ et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005; 106: 2530-2533.
5. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
6. Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/ t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28: 3890-3898.
7. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28: 2101-2107.
8. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3: 207-220.
9. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja SC, Coillard L, Chatterjee G et al. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood 2011; 118: 3853-3861.
10. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med 2011; 208: 2403-2416.
11. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
12. Maetzig T, Brugman MH, Bartels S, Heinz N, Kustikova OS, Modlich U et al. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood 2011; 117: 3053-3064.
13. Wolf S, Rudolph C, Morgan M, Busche G, Salguero G, Stripecke R et al. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas. Oncogene; e-pub ahead of print 30 July 2012; doi: 10.1038/onc.2012.329.
14. Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia 2011; 25: 874-877.
15. Konrad TA, Karger A, Hackl H, Schwarzinger I, Herbacek I, Wieser R. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol 2009; 86: 813-822.
16. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617-3628.
17. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005; 106: 3932-3939.
18. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cellculture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
19. Sellers S, Gomes TJ, Larochelle A, Lopez R, Adler R, Krouse A et al. Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Mol Ther 2010; 18: 1633-1639.
20. Magnusson M, Brun AC, Miyake N, Larsson J, Ehinger M, Bjornsson JM et al. HOXA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development. Blood 2007; 109: 3687-3696.
21. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
22. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6- methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400.
23. Li Z, Schwieger M, Lange C, Kraunus J, Sun H, van den Akker E et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 2003; 31: 1206-1214.
24. Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 2005; 105: 4314-4320.
25. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
26. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 2009; 25: 415-416.
27. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
28. Smyth G, Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL et al. Limma: linear models for microarray data. In: Gentleman R(ed)Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005, pp 397-420.
29. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
30. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, Lu TH et al. GeneSigDB-a curated database of gene expression signatures. Nucleic Acids Res 2010; 38: D716-D725.
31. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
32. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
33. Forsberg EC, Prohaska SS, Katzman S, Heffner GC, Stuart JM, Weissman IL. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet 2005; 1: e28.
34. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006; 26: 1888-1897.
35. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003; 22: 4118-4127.
36. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005; 24: 3397-3408.
37. Einav U, Tabach Y, Getz G, Yitzhaky A, Ozbek U, Amariglio N et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 2005; 24: 6367-6375.
38. Mathew R, Seiler MP, Scanlon ST, Mao AP, Constantinides MG, Bertozzi-Villa C et al. BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. Nature 2012; 491: 618-621.
39. Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011; 118: 1069-1076.
40. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011; 117: 2022-2032.
41. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol; e-pub ahead of print 15 July 2012; doi:10.1155/2012/170325.
42. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008; 27: 5975-5987.
43. Karakaya K, Herbst F, Ball C, Glimm H, Krämer A, Löffler H. Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase. Cell Cycle 2012; 11: 3492-3503.
44. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
45. Kohlmann AL, Bullinger C, Thiede M, Schaich S, Schnittger KD, Döhner K et al. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 2010; 24: 1216-1220.
46. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120: 681-693.
47. Kustikova OS, Geiger H, Li Z, Brugman MH, Chambers SM, Shaw CA et al. Retroviral vector insertion sites associated with dominant hematopoietic clones mark 'stemness' pathways. Blood 2007; 109: 1897-1907.
48. Matsumoto A, Takeishi S, Kanie T, Susaki E, Onoyama I, Tateishi Y et al. p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011; 9: 262-271.
49. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
50. Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14: 505-513.
51. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
52. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-1927.
53. Aguilo F, Avagyan S, Labar AS, Sevilla A, Lee DF, Kumar P et al. Prdm16 is a physiological regulator of hematopoietic stem cells. Blood 2011; 117: 5057-5066.
54. Chuikov S, Levi BP, Smith ML, Morrison SJ. Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nat Cell Biol 2010; 12: 999-1006.
55. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, Li Z et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008; 22: 1519-1528.
56. Tesio M, Trumpp A. Breaking the cell cycle of HSCs by p57 and friends. Cell Stem Cell 2011; 9: 187-192.